ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod

Clinical trial NCT07284420 · RECRUITING

Trial details

NCT number: NCT07284420
Sponsor: argenx
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

AChR-Ab Seropositive Generalized Myasthenia Gravis Myasthenia Gravis MG gMG Generalized Myasthenia Gravis Generalized Myasthenia Gravis (gMG)

Start date: 2025-12-19
Primary completion: 2028-03-07
Enrollment: 70

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.